COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts treated w/ ADA re-randomized to IXE showed further⬇️in SP-N & spinal pain. Poster #POS0901 #EULAR2021 @RheumNow https://t.co/46qiqrohbX https://t.co/uB15oTwztV

• https://ard.bmj.com/content/80/Suppl_1/707.2

We are truly blessed to live in an era when response to RA treatment is the norm. (our forefathers looking on jealously from their gold and pencillinamine towers!) real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv

German SpA Inception Cohort analyses: TNFi assc w/ ⬇️ sacroiliitis and spinal dz progression in axSpA pts, but the effect is evident starting between 2 and 4 years post tx induction. #EULAR2021 Abstracts #OP0137 & #OP0139 @RheumNow https://t.co/uR9rug6zqI https://t.co/xF3wcxm4cf https://t.co/lEsUvOSJ6K

• http://ow.ly/hBIr50F1kuS
• https://ard.bmj.com/content/80/Suppl_1/81

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

#EULAR2021 #EULAR21 #eular #spondyloarthritis I have always thought we named nr-axSPA wrongly - Tends to trivialise its gravity and importance Shouldn’t it be our goal to diagnose all SpA at the nr-axSPA stage @deodhara @NigilHaroon https://t.co/zwKI1o9WcO

#EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA patients among real-world patients in CorEVitas' Psa/Spa observational Registry per Dr. Mease's oral abstract presentation. @RheumNow https://t.co/YEdhd7x6cb

#EULAR2021 - Key points from Dr. Mease's oral abstract: ⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD ⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts ⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status @Rheumnow